All dates are flexible as we have seen a number of
Post# of 30028
(Total Views: 338)
Posted On: 12/29/2018 12:05:30 PM
All dates are flexible as we have seen a number of times.
I think too many times people put it as, it better happen by this date or the whole world is ending only to find out that the world did not end.
The language for the HK exchange was from the original PR with PGI Drug Discovery LLC. Also in that PR
5 A. Such Merger must be completed by December 15th, 2018;
6. PGI may terminate the Elto License for certain breaches, including failure to complete the merger by December 15th, 2018.
As you can see the original drop dead date was also the same date the new meger agreement was signed.
On December 15th, 2018, the Company entered into the definitive Merger Agreement between Elto Pharma, Inc. and Coeptis Pharmaceuticals, Inc. Under the terms of the agreement, Coeptis will issue 7.5 million shares of Coeptis common stock to shareholder of Elto Pharma, Inc., then representing 1/3 of outstanding Coeptis shares outstanding, in exchange for all of the shares of Elto Pharma, Inc. An additional 7.5 million shares of Coeptis common shares are issuable upon the earlier of:
1) Successful completion of a Phase 2b trial for eltoprazine in Parkinson’s levodopa-induced dyskinesia; or
2) New Drug Application approval by US FDA for eltoprazine in any indication.
Key closing conditions for the Elto Pharma, Inc. and Coeptis Pharmaceuticals Merger Agreement include:
1. Payment of Psychogenics, Inc. legal fees by December 31st, 2018;
2. Acquisition of D&O insurance by January 15, 2019;
3. Coeptis raising a minimum of $6M dedicated towards the development of eltoprazine by April 5, 2019.
And as we can see the world has not ended. They have not terminated anything.
I believe it is still either HK and or NYSE. With the preference being NYSE.
A few things that stand out are 2 dates, Dec. 31st & Jan 15th. But again dates and always be worked around.
I really like the option of this being in there!
2) New Drug Application approval by US FDA for eltoprazine in any indication.
Cause #1 could take some time, but I imagine this is already deep in the works...
Overall from the entirety the reads as the best company overview in while.
AMBS is now on its proper path
2019 will be fun watching all of this play out.
The notes were minimal on the Reg A+. Also, that was done on the DL, no clue as of yet on whether or not GC has filed the answers and or will they need time into mid or late Q1 to answer. I don't think so.
Once they get word that they can, they will announce the price offering and open it up.
R emeber what the Reg A+ is for and what will happen once achieved.
Aloha
I think too many times people put it as, it better happen by this date or the whole world is ending only to find out that the world did not end.
The language for the HK exchange was from the original PR with PGI Drug Discovery LLC. Also in that PR
5 A. Such Merger must be completed by December 15th, 2018;
6. PGI may terminate the Elto License for certain breaches, including failure to complete the merger by December 15th, 2018.
As you can see the original drop dead date was also the same date the new meger agreement was signed.
On December 15th, 2018, the Company entered into the definitive Merger Agreement between Elto Pharma, Inc. and Coeptis Pharmaceuticals, Inc. Under the terms of the agreement, Coeptis will issue 7.5 million shares of Coeptis common stock to shareholder of Elto Pharma, Inc., then representing 1/3 of outstanding Coeptis shares outstanding, in exchange for all of the shares of Elto Pharma, Inc. An additional 7.5 million shares of Coeptis common shares are issuable upon the earlier of:
1) Successful completion of a Phase 2b trial for eltoprazine in Parkinson’s levodopa-induced dyskinesia; or
2) New Drug Application approval by US FDA for eltoprazine in any indication.
Key closing conditions for the Elto Pharma, Inc. and Coeptis Pharmaceuticals Merger Agreement include:
1. Payment of Psychogenics, Inc. legal fees by December 31st, 2018;
2. Acquisition of D&O insurance by January 15, 2019;
3. Coeptis raising a minimum of $6M dedicated towards the development of eltoprazine by April 5, 2019.
And as we can see the world has not ended. They have not terminated anything.
I believe it is still either HK and or NYSE. With the preference being NYSE.
A few things that stand out are 2 dates, Dec. 31st & Jan 15th. But again dates and always be worked around.
I really like the option of this being in there!
2) New Drug Application approval by US FDA for eltoprazine in any indication.
Cause #1 could take some time, but I imagine this is already deep in the works...
Overall from the entirety the reads as the best company overview in while.
AMBS is now on its proper path
2019 will be fun watching all of this play out.
The notes were minimal on the Reg A+. Also, that was done on the DL, no clue as of yet on whether or not GC has filed the answers and or will they need time into mid or late Q1 to answer. I don't think so.
Once they get word that they can, they will announce the price offering and open it up.
R emeber what the Reg A+ is for and what will happen once achieved.
Aloha
(5)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼